Both prolactin (PRL) and estrogen (E2) are involved in the pathogenesis and progression of mammary neoplasia, but the mechanisms by which these hormones interact to exert their effects in breast cancer cells are not well understood. We show here that PRL is able to activate the unliganded estrogen receptor (ER). In breast cancer cells, PRL activates a reporter plasmid containing estrogen response elements (EREs) and induces the ER target gene pS2. These actions are blocked by the antagonist ICI 182,780, showing that ER is required for the PRLmediated effect. Moreover, PRL leads to phosphorylation of ERa in serine-118 (P-ERa), a modification related to the potentiation of ligand-independent transcriptional activation. In addition, PRL mimics the effect of E2 on target gene expression by inducing cyclical recruitment of ERa and P-ERa to ERE-containing promoters, resulting in recruitment of co-activators and acetylation of histone H3. Finally, PRL induces expression of c-Myc and Cyclin D1 and leads to increased cell proliferation, which is specifically antagonized by ICI 182,780 or ERa depletion. These results show that ligand-independent ERa activation appears to be an important component of the proliferative and transcriptional actions of PRL in breast cancer cells.
Introduction
Prolactin (PRL) has a key function in mammary gland development and PRL involvement in breast cancer has now been clearly established. Both the hormone and its receptor are expressed in mammary tumors and in breast cancer cell lines, thereby creating autocrine/ paracrine modes of action for PRL (Clevenger et al., 1995; Ginsburg and Vonderhaar, 1995; Touraine et al., 1998; Schroeder et al., 2002) . Different studies have correlated PRL levels with breast cancer incidence, showing that prolactin receptor (PRLR) levels are generally higher in breast tumors than in normal mammary tissue (Clevenger et al., 2003; Tworoger and Hankinson, 2006) . Furthermore, disruption of PRL signaling in breast cancer cells causes cell growth inhibition apoptosis induction (Fuh and Wells, 1995) .
Different signaling pathways that are activated on PRL binding to its receptor have been demonstrated to lead to breast cancer cell proliferation. In breast cancer cell lines PRL stimulates both the JAK1 and JAK2 pathways (Campbell et al., 1994; Liu et al., 1997; Neilson et al., 2007) , and we have previously demonstrated that PRL stimulates Src kinases, which then independently activate Fak/ERK1/2 and the PI3K-dependent p70S6K and Akt kinases (Acosta et al., 2003) . Activated ERK1/2 and AKT lead among others to increased AP-1 complexes, and induce the expression of cell-cycle progression genes such as cyclin D1 or c-myc (Brockman et al., 2002; Acosta et al., 2003; Gutzman et al., 2005) .
Estrogen is also involved in normal breast development, as well as in growth and progression of breast cancer. The biological actions of estrogens are mediated by binding to nuclear estrogen receptors (ERa and ERb). In breast cancer cells expressing ERs, estradiol (E2) has potent proliferative effects and treatment with ER antagonists is the current hormone therapy of choice for the treatment of ERa-positive breast cancers (Yager and Davidson, 2006) . A key event for the antiproliferative effects of antiestrogens appears to be the downregulation of Cyclin D1 and c-Myc (Musgrove et al., 1993; Carroll et al., 2002) .
Normally, ERs act as ligand-dependent transcription factors by binding as homodimers to estrogen response elements (EREs) in target genes (Aranda and Pascual, 2001) . However, there is increasing evidence that the presence of estrogen is not an absolute requirement for receptor activation, because growth factors, such as IGF-1 or EGF, and intracellular protein kinases can induce an estrogen-independent ERa activation in different model systems (Butt et al., 2005) . In breast cancer cells phosphorylation of the Ser-118 residue in the human ERa A/B domain by growth factors stimulated mitogen-activated protein kinase (Kato et al., 1995; Bunone et al., 1996; Chen et al., 2000; Medunjanin et al., 2005; Park et al., 2005; Weitsman et al., 2006) results in the potentiation of the ER ligandindependent transcriptional activation function (AF-1). Interestingly, it has been proposed that phosphorylation in Ser-118 may be associated with an increase in estrogen agonism, progression of breast cancer, resistance to tamoxifen therapy and estrogen-independent growth of MCF-7 cells (Likhite et al., 2006; Murphy et al., 2006) . Recently, it has been shown that the pure ER antagonist ICI 182,780 (ICI) can also induce ER phosphorylation in Ser-118 (Lipfert et al., 2006; De los Santos et al., 2007) .
In the normal mammary gland PRL and estrogen act synergistically to favor mammary gland growth and development (Hennighausen and Robinson, 2005) . ERa and PRLR are co-expressed in many breast tumors (Murphy et al., 1984; Ormandy et al., 1997) . However, the mechanisms by which these hormones interact to affect breast cancer cell functions are not completely understood. One of the mechanisms of PRL and estrogen interaction is the cross-regulation of their receptors (Ormandy et al., 1997; Dong et al., 2006) . It has been described that PRL increases ERa levels and E2 responsiveness in breast cancer cells (Shafie and Brooks, 1977; Gutzman et al., 2004a) . In addition, both PRL and E2 increase ERK1/2 phosphorylation and cooperatively activate the transcription factor AP-1 (Gutzman et al., 2004b (Gutzman et al., , 2005 . However, the possibility that PRL could also mediate some of its actions by inducing estrogen-independent ERa activation has not been yet explored.
In this study we show that PRL increases ER activity in an estrogen-independent manner in T47D and MCF-7 cells. We found that PRL induces Ser-118-ER phosphorylation, increases the activity of an EREcontaining reporter plasmid, upregulates the expression of the ER-dependent gene pS2 and induces the recruitment of ERa and co-activators to ER target promoters. Moreover, ICI abolishes the effect of PRL on ERE stimulation and pS2 gene expression and blocks PRLdependent proliferation, demonstrating that ligandindependent ER activation by PRL is an important mediator of the mitogenic and transcriptional effects of this hormone in breast cancer cells.
Results

PRL-dependent activation of unliganded ER
To explore the interaction between PRL and ERs, we analysed the effect of this hormone on the transcription of an estrogen-responsive reporter plasmid. As shown in Figure 1a , treatment of T47D cells with PRL, in the absence of E2, caused a significant increase in luciferase activity at the different time points examined. To prove that the effect of PRL on the reporter plasmid was due to ER activation, cells were incubated either with PRL or with E2 for 6 and 40 h in the absence and presence of ICI. As shown in Figure 1b , the ER antagonist blocked not only the response to E2 but also to PRL.
To determine the effect of PRL on endogenous ERdependent gene expression, we analysed transcripts for the well-known estrogen target gene pS2, containing EREs in its regulatory region (Nunez et al., 1989) . PRL significantly induced pS2 mRNA levels in T47D cells (Figure 2a) , without increasing ERa mRNA levels (Figure 2b ). PRL-mediated transcription was abolished when cells were treated with the ER antagonist, further demonstrating that the lactotrophic hormone can stimulate the unliganded ER.
PRL induces Ser-118-ERa phosphorylation Post-translational modifications of ERa are emerging as important regulatory elements of cross talk between different signaling pathways. In particular, phosphorylation at Ser-118 has been implicated in the liganddependent and -independent effects of ERa and in tamoxifen resistance of breast tumors (Lonard et al., 2000; Wijayaratne and McDonnell, 2001; Murphy et al., 2004) . Thus, we analysed the effect of incubation with PRL on ERa phosphorylation in Ser-118 (P-ERa) by western blot. As shown in Figure 3a , incubation with PRL caused a rapid and sustained increase of P-ERa levels, whereas total ERa levels remained unchanged through the period in which increased phosphorylation was observed. Similar results were obtained in MCF-7 cells (Figure 3b) , demonstrating that the effect of PRL is not restricted to the T47D cell line. We also assessed the effect of ICI on PRL-induced ERa phosphorylation (Figure 3c ). Short-term incubation with ICI increased the effect of PRL on P-ERa levels, but reduced phosphorylation was observed after 6 h of incubation, due to the expected strong downregulation of ERa expression caused by ICI (Lonard et al., 2000; Wijayaratne and McDonnell, 2001 ). This reduction was not observed when PRL was combined with the ER antagonist tamoxifen that does not induce receptor downregulation, and under these conditions a strong phosphorylation was found after 24 h of incubation in the presence of both compounds (Figure 3d ). Finally, induction of Ser-118 phosphorylation by PRL was blocked in the presence of the inhibitors PD184352, LY294002 and PP2 (Figure 3e) , showing that ERK and PI3K activation that we have previously shown to be secondary to c-Src stimulation (Acosta et al., 2003) are required to induce receptor modification.
PRL induces ERa recruitment to estrogen target genes Estrogen-dependent transcriptional activation has been shown to involve occupancy of the target promoter by ER (Shang et al., 2000; Metivier et al., 2003) and P-Ser-118-ERa is also recruited to the promoters of estrogenregulated genes . To analyse whether treatment of breast cancer cells with PRL could also induce the recruitment of ERa and P-Ser-118-ERa to the target promoter, we performed chromatin immunoprecipitation (ChIP) assays in a-amanitin-synchronized populations of cells to compare pS2 promoter occupancy by the receptor in T47D cells incubated with PRL or E2. As shown in Figure 4 , E2 recruited ERa to the pS2 promoter region containing the ERE and known to be required for E2 regulation of transcription (Nunez et al., 1989) . This binding increased at 40 min and then decreased, in agreement with data obtained in other breast cancer cell line (MCF-7), where ERa recruitment to the promoter is cyclical (Shang et al., 2000; Metivier et al., 2003) . Interestingly, PRL induced ER binding to the pS2 promoter with similar kinetics. Moreover, we observed that the phosphorylated receptor was also recruited in response to both hormones. P-Ser-118-ERa was essentially absent from the promoter in the untreated cells, but was already associated after 20 min of incubation with either E2 or PRL, decreasing at 60 min and increasing again at 80 min. These changes were specific for the ERE-containing region because no ER recruitment was observed when an irrelevant upstream region of the promoter was amplified. The effect of PRL applies to other ER target promoters, as demonstrated by a significant recruitment of ERa and P-Ser-118-ERa to the ERE-containing GREB1C promoter (Bourdeau et al., 2004) in response to PRL. In addition, PRL as well as E2 caused pS2 promoter occupancy by ERa and P-Ser-118-ERa in MCF-7 cells (Supplementary Figure 1) , showing that this finding can be extended to other breast cancer cell lines.
Nuclear receptors stimulate transcription by recruitment of co-activators that lead to local alteration of chromatin structure generated by post-translational Prolactin activates the estrogen receptor L González et al modifications of histones such as acetylation (Aranda and Pascual, 2001 ). Therefore, we examined, by ChIP, the effect of PRL on the binding of the p160 coactivator SRC-1 and acetylated histone H3 to the pS2 promoter. As illustrated in Figure 5 , PRL-and E2-induced ER binding correlated with the recruitment of the co-activator and increased promoter acetylation. These data are consistent with the occupancy of estrogen-regulated promoters by ERa and P-Ser-118-ERa in response to PRL treatment, strongly suggesting that ligand-independent receptor recruitment may represent a mechanism for transcriptional regulation of ER-target genes by PRL.
ICI blocks PRL-dependent breast cancer cell proliferation
Previous studies have demonstrated that PRL induces moderate T47D cell growth (Acosta et al., 2003) . The ability of ICI to antagonize the effect of PRL on transcription suggested that this compound could also suppress PRL-dependent cell proliferation. As shown in Figure 6a , incubation of T47D cells with PRL induced an increase of [ 3 H]thymidine incorporation. The moderate activation of cell proliferation above basal levels induced by PRL may be due to the fact that these cells produce PRL, which by an autocrine/paracrine feedback loop can affect breast cancer cells even under serum-free media conditions (Clevenger et al., 1995; Reynolds et al., 1997; Schroeder et al., 2002) . In addition, ICI (from nanomolar to millimolar concentrations) caused a marked reduction of [ 3 H]thymidine uptake and abolished the mitogenic effect of PRL. ICI also blocked the increase in T47D cell number triggered not only by E2 but also by PRL (Figure 6b ). To further examine the effect of PRL and ICI on breast cancer cell proliferation, flow cytometry analysis was performed in T47D and MCF-7 cells. Most cells were in G 0 /G 1 as corresponding with serum starvation, but PRL treatment caused a modest but consistent reduction in the number of cells in this phase of the cell cycle and induced a concomitant increase in the percentage of cells in S phase. Significantly, incubation with ICI abolished the effect of PRL in both T47D (Figure 6c ) and MCF-7 cells (Supplementary Figure 2) . These results suggest again that ER activity is required for the proliferative response of breast cancer cells to the lactotrophic hormone. To prove this point, ERa was knocked down by means of short-interfering RNA (siRNA) in T47D cells (Figure 6d) , and the effect of PRL on the cell cycle was analysed by flow cytometry (Figure 6e ). Stimulation of cell-cycle progression by PRL was abolished in ERadepleted cells, indicating that this receptor is required for PRL-induced proliferation. As expected, the mitogenic effect of E2 was also abolished in cells transfected with siERa.
Prolactin-induced proliferation of breast cancer cells appears to require ERK1/2 and AKT activation. Therefore, it was possible that ICI could inhibit the effect of the polypeptide hormone on proliferation by blocking activation of these kinases. However, incubation with PRL for different time periods was equally effective in stimulating ERK1/2 and PI3K activity in the presence and absence of ICI in T47D (Figure 7a ) and MCF-7 cells (Supplementary Figure  3A) . In addition, lowering ERa by means of siRNA did not block phosphorylation (Figure 7b ). Prolactin-stimulated mitogenic signaling cascades ultimately induce the expression of c-Myc and Cyclin D1 (Acosta et al., 2003) , which are critical molecules for G 1 /S cell-cycle progression. We therefore evaluated whether ICI could block the effect of PRL on expression of these proteins. As illustrated in Figure 7c , and in agreement with its effect on proliferation, PRL induced a detectable increase of cell-cycle proteins in T47D cells.
At short incubation times ICI was unable to repress c-Myc or Cyclin D1 levels. However, at incubations longer than 6 h, and concomitant with ERa depletion, ICI caused a marked reduction of these proteins, reversing PRL induction and lowering expression to levels below those of untreated T47D cells. Similar results were obtained in MCF-7 cells in which ICI also caused a time-dependent reduction of Cyclin D1 expression (Supplementary Figure 3B) .
Recently, it has been reported that Cyclin D1 induction by E2 involves ERa recruitment to an enhancer located downstream from the coding region (Eeckhoute et al., 2006) . We therefore analysed by ChIP binding of ERa and P-Ser-118-ERa to this enhancer (enh 2), as well as to an upstream promoter region (enh 1) also shown to bind ERa (Eeckhoute et al., 2006) . Incubation not only with E2 but also with PRL caused association of total and phosphorylated ERa with these regions both in T47D (Figure 8a ) and MCF7 cells (Figure 8b ), thus providing a link between PRL and breast cancer cell proliferation.
Discussion
ERa normally acts as a transcription factor in response to binding of its cognate ligand. However, there is increasing evidence that the presence of estrogen is not an absolute requirement for activation of this receptor, because growth factors such as IGF-1 or EGF and intracellular protein kinases can induce an ERa activation independently of ligand binding (Butt et al., 2005) . In this work we show that PRL can also activate ER in Histone H3 acetylation and co-activator recruitment at the pS2 promoter. Binding of ERa, the p160 co-activator SRC-1 and acetylated histone H3 (H3-Ac) to the proximal pS2 promoter and to an irrelevant region was determined by chromatin immunoprecipitation (ChIP) assay after treatment of T47D cells with E2 and prolactin (PRL) as indicated. Normal immunoglobulin G (IgG) was used as a negative control.
Prolactin activates the estrogen receptor L González et al breast cancer cells leading estrogen-independent induction of ER target gene expression. We have demonstrated that PRL increases ERE activity in transient transfection assays and also induces transcription of the endogenous ER target gene pS2, considered a marker of breast cancer progression and as a resistance predictor of breast tumors to ER antagonists (Johnston et al., 1995) . These actions are observed in serum-free medium lacking phenol red and therefore most likely represent ligand-independent receptor activation, but we cannot ignore the possibility that PRL could synergize with residual levels of estrogen. The effects of PRL are abolished by the pure antagonist ICI, demonstrating the involvement of ER activation. Moreover, we show that PRL mimics the effect of E2 promoting the recruitment of ERa to endogenous target promoters, independently of E2. PRL-induced binding of ERa to the promoter determines co-activator recruitment and histone acetylation, both landmarks of receptor-mediated transcriptional activation. Increased ERa levels are common in breast cancer (Fabris et al., 1987; Holst et al., 2007) and have been associated with aberrant promoter occupancy, increased gene expression and cell proliferation in the absence of hormonal stimulation (Fowler et al., 2004) . Because it has been reported that PRL increases ERa levels in breast cancer cells (Shafie and Brooks, 1977; Gutzman et al., 2004a) , the stimulatory effect of PRL on the ER target genes could be due to ERa induction. However, we did not observe increased receptor expression over the period in which PRL stimulates ER-dependent gene transcription.
It has been proposed that phosphorylation in the AF-1 domain is associated with estrogen-independent ER activation. Ser-118 is a well-studied phosphorylation site in ERa and both ER ligands and growth factors can induce this modification (Kato et al., 1995; Bunone et al., 1996; Chen et al., 2000 Chen et al., , 2002 . Our results show that PRL signaling pathways cause a rapid and sustained Ser-118-ERa phosphorylation. Chemical inhibition of Src, ERK or AKT abolishes receptor phosphorylation by PRL. This is surprising because the inhibitors used are accepted to be specific and a partial reduction would have been predicted if multiple pathways are involved in phosphorylation. Interestingly, we have reported that each of these inhibitors also blocks PRL-induced breast cancer cell proliferation (Acosta et al., 2003) , and these pathways are also required for the mitogenic effects of estrogen (Migliaccio et al., 1996 (Migliaccio et al., , 1998 .
Our results also show that PRL causes recruitment of the phosphorylated receptor to target promoters. Therefore, increased receptor modification could also contribute to the activation of ER-dependent gene transcription secondary to PRL treatment in breast cancer cells. However, it should be noted that this modification cannot be univocally linked to transcriptional activation, because ER antagonists also cause Ser-118-ERa phosphorylation (Lipfert et al., 2006) . In fact, we have previously shown that ICI is at least as strong as E2 to induce a sustained increase of Ser-118-ERa phosphorylation in MCF-7 cells (De los Santos et al., 2007) , and in this work we observe that ER antagonists cooperate with PRL to increase P-Ser-118-ERa levels. In addition to ERa phosphorylation, the activation of ERK1/2 and AKT by PRL may also lead to phosphorylation of receptor co-regulators (co-activators and co-repressors). This modification alters their Prolactin activates the estrogen receptor L González et al activity, their interaction with transcription factors and their cellular redistribution (Jonas and Privalsky, 2004; Wu et al., 2005) and could therefore contribute to PRLdependent transcriptional stimulation. Furthermore, it has been demonstrated that induction of progesterone target genes in breast cancer cells involves activation of the ERK1/2 cascade and phosphorylation of histone H3, as a prerequisite for recruitment of co-activators and transcriptional activation (Vicent et al., 2006) . It is plausible that activation of this signaling pathway by PRL could also induce histone H3 phosphorylation, promoting the transcription of ER target genes.
Both E2 and PRL induce breast cancer cell growth by modifying the expression of key regulatory components of cell-cycle progression such as Cyclin D1 or c-Myc (Musgrove et al., 1993 (Musgrove et al., , 1994 Carroll et al., 2002; Schroeder et al., 2002; Acosta et al., 2003) . These proteins are frequently overexpressed in human breast cancers and have been implicated in the development of mammary hyperplasia and carcinogenesis (McNeil et al., 2006; Wang et al., 2007) . We have confirmed that PRL induces moderate Cyclin D1 and c-Myc expression, and that the anti-estrogen counteracts their induction, as well as PRL-dependent breast cancer cell growth. The finding that induction of these proteins by PRL is modest has been attributed to the production of PRL within the mammary cells themselves, because in MCF-7 cells that do not express endogenous PRL treatment with the hormone has strong effects on the levels of cell-cycle regulators and on cell proliferation .
The fact that repression of cell-cycle proteins by ICI is concomitant with ERa downregulation reinforces the idea that ER activation is involved in the effect of the lactotrophic hormone on breast cancer cell proliferation. There was the possibility that the ability of ICI to repress cell proliferation in the presence of PRL could simply indicate that the ER antagonist targets processes essential for cell-cycle progression rather than inhibiting processes activated by PRL. However, we found that depletion of ERa with siRNA was able to block the mitogenic effect of PRL, demonstrating a key function for ERa in this hormonal action. In contrast, other PRL actions such as ERK activation appear to be ERa independent, because they are not blocked by treatment with ICI or by ERa downregulation.
In summary, our results indicate a novel layer of complexity in the interaction between ER and PRL signaling in breast cancer. The finding that the polypeptide hormone can activate ERa in a ligand- independent manner evidences the significance of this mechanism in the development of breast cancer and suggests that anti-estrogen therapy acts not only by inhibiting E2 actions but also by antagonizing PRL effects on breast cancer cells. Cell culture and transfection T47D and MCF-7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin, and 72 h before transfection were shifted to serum-free medium lacking phenol red. Cells were transiently transfected with 5 mg of a luciferase reporter plasmid that contains three copies of a consensus ERE by incubation with a mixture of cationic liposomes (1.5 ml/mg DNA) for 6 h (De los Santos et al., 2007) . Cells were then treated with 100 nM PRL, ICI or E2 for the indicated times, and luciferase activity was determined. Experiments were performed with triplicate cultures and each experiment was repeated at least three times. Data are represented as means ± standard deviations. siRNA for ERa and non-target control were purchased from Dharmacon (catalogue nos. L-003401-00 and D-001210-01-05). siRNA transfections were performed using 33 nM of each siRNA and Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), as recommended by the manufacturer. The efficiency of knockdown was determined by western blot.
Materials and methods
Materials
Cell proliferation
Exponentially growing T47D cells were inoculated in 24-well plates, and 24 h later were washed and shifted to serum-and phenol-free medium. Cells were kept in this medium for 48 h and then treated for 72 h with PRL and/or ICI, and for the last 4 h with 0.5 mCi per well of [ 3 H]thymidine (48 Ci/mmol). Cells were disrupted and incorporated radioactivity was determined 
Cyclin D1 enh 2 Cyclin D1 enh 1 Figure 8 Prolactin (PRL) induces recruitment of P-ERa and ERa to the cyclin D1 gene sites responsible for E2 induction. Association of ERa and P-Ser-118-ERa to an enhancer located downstream the cyclin D1 coding region (enh 2), and to an upstream enhancer located at À2000 (enh 1). Binding was determined by chromatin immunoprecipitation (ChIP) assays in T47D (a) and MCF-7 cells (b) at the indicated time points of incubation with E2 and PRL. The upper panels show the inputs for each ChIP and the lower panels the results obtained with the ERa and P-ERa antibodies and with normal immunoglobulin G (IgG) used as a negative control.
Prolactin activates the estrogen receptor L González et al in a liquid scintillation Beta Wallac Counter. Alternatively, cells were inoculated in 60 mm Petri dishes and the number of cells was counted in Neubauer chambers after treatment with PRL or E2 alone or in combination with ICI.
Flow cytometry
Duplicate cultures of T47D and MCF-7 cells grown in 60 mm Petri dishes were transferred to the serum-and phenol-reddepleted medium and after 72 h incubated with PRL and/or ICI for different time periods. Cells were collected and stained with propidium iodide for sorting as previously described (De los Santos et al., 2007) .
Western blot
Cells previously incubated for 48 h in serum-and phenol-reddepleted medium were treated with PRL (100 ng/ml) alone or in combination with ICI or tamoxifen (100 nM) for the times indicated. Antagonists were added 2 h before PRL. Cells were washed twice in ice-cold Tris-buffered saline (20 mM Tris-HCl, pH 7.6; 140 mM NaCl) with 0.1 mM Na 3 VO 4 and lysed at 4 1C in 1 ml of lysis buffer (10 mM Tris-HCl, pH 7.6; 50 mM NaCl; 30 mM sodium pyrophosphate; 5 mM EDTA; 0.5% Nonidet P-40; 1% Triton X-100; 50 mM NaF; 0.1 mM Na 3 VO 4 ; 1 mM phenylmethylsulfonylfluoride; 1 mM benzamidine; 1 mM iodoacetamide and 1 mM phenantroline). Cell lysates were obtained by centrifugation at 17 000 g for 15 min at 4 1C, protein concentration in the supernatant was determined by the BCA protein assay (Pierce Chemical Co, Rockford, IL, USA), and lysates were adjusted to equivalent concentrations with lysis buffer. Proteins from cell lysates were separated in SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Immobilon; Millipore, Billerica, MA, USA) that were blocked for 1 h at room temperature with 4% bovine serum albumin. Incubation with antibodies was performed in blocking solution for 1 h at room temperature. Blots were visualized with enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech). Rabbit polyclonal antibodies to Erk2 (C14), Akt (H-136), c-Myc (9E10) and Cyclin D1 (H-295) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The ERa antibodies used were either from Dako (1D5) (Carpinteria, CA, USA) or a kind gift of S Ramos. The later antibody detects a doublet where the upper band is the nonspecific. Antiphospho antibodies to pErk1/2, pAkt and pSer-118-ERa were from New England Biolabs (Beverly, MA, USA). Secondary horseradish-peroxidase-conjugated antibodies were purchased from BioSource International (Camarillo, CA, USA), and the ECL kit was from Amersham Pharmacia Biotech. Primary antibodies were used at a 1:1000 dilution.
Real-time PCR
Cells were cultured for 48 h in depleted medium before incubation with PRL and/or ICI. Total RNA was extracted using Tri Reagent (Sigma) and mRNA levels were analysed by quantitative real-time PCR. RT was performed with 2 mg of RNA following specifications of SuperScript First-Strand Synthesis System (Invitrogen Life Technologies). PCR reactions were performed in a Mx3005P thermocycler (Stratagene) and detected with SYBR Green using the following primers: pS2 5 0 -tcccctggtgcttctatcctaa-3 0 (forward) and 5 0 -AGTGTCTA AAATTCACACTCCTCTTCT-3 0 (reverse), and ERa 5 0 -CCA CCAACCAGTGCACCATT-3 0 (forward) and 5 0 -GGTCTT TTCGTATCCCACCTTTC-3 0 (reverse). Values obtained were corrected by glyceraldehyde-3-phosphate dehydrogenase expression determined with primers 5 0 -ACAGTCCATGCCATC ACTGCC-3 0 (forward) and 5 0 -ctagctgacctccttgacctg-3 0 (reverse). Results were analysed by the C T comparative method (DDC T ).
ChIP assays
Cells growing in p150 dishes were maintained in depleted medium for 72 h, washed twice in serum-free medium and treated for 2.5 h with 2.5 mM a-amanitin (Sigma). As previously described this treatment is required for a preliminary silencing of the pS2 promoter (Metivier et al., 2003) . Cells were then washed and treated with PRL or E2. At the indicated time points, cells were fixed with 1% formaldehyde for 15 min at 37 1C. The Chromatin Immunoprecipitation Assay kit from Upstate (catalogue no. 17-295) was used. Sonication was performed using a Bioruptor UCD-200TM (Diagenode) following manufacturer's directions. For each immunoprecipitation 2.5-3.0 Â 10 6 cells and 3 mg of the following antibodies: anti-acetylated histone 3 (06-599; Upstate, Lake Placid, NY, USA), anti-SRC-1 (sc-8995), anti-ER (sc-542), anti-pSer-118-ERa (sc-12915-R) and normal rabbit serum immunoglobulins (sc-2027) were used. DNAs were subjected to 35 cycles of PCR with primers: forward 5 0 -GCCATCTCTCACTAT GAATC-3 0 and reverse 5 0 -GGATTTGCTGATAGACAGAG-3 0 to amplify the ERE-containing pS2 promoter region (À392/À199 bp); forward 5 0 -CAGTCTGGCAAATCATTCC CAAAC-3 0 and reverse 5 0 -CACATCTGAGAGGTAAGAG GAGGTG-3 0 to amplify an irrelevant pS2 region ; forward 5 0 -TTGTTGTAGCTCTGGGAGCA-3 0 and reverse 5 0 -CAACCAGCCAAGAGGCTAAG-3 0 to amplify the proximal GREB1C promoter region that contains the ERE; forward 5 0 -CAGTTTGTCTTCCCGGGTTA-3 0 and reverse 5 0 -TCATCCAGAGCAAACAGCAG-3 0 to amplify the downstream enhancer (enh 2) of the cyclin D1 gene; and forward 5 0 -GCTCTTTACGCTCGCTAACC-3 0 and reverse 5 0 -GGGCAGATCTCGACTAGGAA-3 0 to amplify the upstream ER binding region (enh 1) of this gene (Eeckhoute et al., 2006) .
